Follow-On Biologics Is Pathway Not Taken, But House Cmte. Talks Continue
Executive Summary
Energy and Commerce Health subcommittee members agreed Oct. 31 that there is not enough time left this session to pursue legislation addressing follow-on biologics
You may also be interested in...
Biogenerics May Get Bounce As FDA Joins Debate; House Panel Eyes Bill
FDA will become an active participant this year in the debate over legislation creating a regulatory pathway for approval of generic biologics
Biogenerics May Get Bounce As FDA Joins Debate; House Panel Eyes Bill
FDA will become an active participant this year in the debate over legislation creating a regulatory pathway for approval of generic biologics
FDA Gets Practical On Follow-On Biologics As Pathway Remains Theoretical
Although a pathway for follow-on biologics has not been established by Congress, FDA is offering industry a description of what some of the paving stones could look like